The DIR and its Annual 2025
The German IVF Registry (Deutsches IVF-Register, DIR) has documented fertility treatments in Germany since 1982. Around 140 fertility centers report their cycles to it, and every year the DIR publishes the results in its annual report, covering national statistics, special analyses and center-specific evaluations. The Annual 2025 is based on 136,770 validated treatment cycles from 138 centers, 3.1% more than the year before (DIR Annual 2025, p. 228).
The key findings
1. Multiple births have fallen sharply. Between 2017 and 2024, the multiple birth rate after fresh embryo transfers fell from 22.0% to 6.7%. After frozen embryo transfers, it fell from 15.4% to 5.1% (p. 232). At the same time, the pregnancy rate per transfer stayed stable at around 30% (pp. 228, 232).
2. Two single transfers beat one double transfer. A registry analysis of 133 centers compared one double embryo transfer (DET) with two consecutive single embryo transfers (SET + SET) for women with at least two blastocysts. The double transfer gave more live births per fresh transfer. But once the second, cryopreserved SET was counted, more women had a live birth after two SETs: 45.6% versus 38.4%. The multiple birth rate was 1.7% instead of 30.3% (p. 231).
3. IVF can be enough. For the first time, the DIR analyzed how sperm quality affects IVF and ICSI outcomes. With normal semen parameters, fertilization, pregnancy, miscarriage and birth rates were comparable between the two. The authors' conclusion: not "ICSI for all", but "IVF when IVF is enough". ICSI remains the better choice for very low concentration or markedly reduced motility (pp. 258-260).
4. Cryopreservation keeps paying off. After four embryo transfers, including frozen ones, 70.8% of patients had achieved a pregnancy (p. 235). Frozen transfers now make up 38.9% of all cycles (p. 232).
Behind every one of these findings stands the same foundation: the treatment data that the participating centers document, cycle after cycle.
"Any evaluation is only as good as the raw data"
The DIR opens its chapter on documentation quality with this sentence, which sums up what a registry stands for (p. 243).
For the DIR, this is more than a motto. In its preface, the DIR describes the registry's quality as unique worldwide and says that colleagues at international conferences regularly call it an exemplary standard (p. 229). The annual team thanks the centers for their meticulous work (p. 243). After all, the raw data come from the daily documentation in the fertility centers.
MedITEX and the DIR
That daily documentation is where MedITEX comes in. MedITEX is software for fertility clinics and IVF labs, covering patient records, treatment cycles, embryology and lab documentation, and reporting. In Germany, MedITEX IVF marks the fields required for the DIR and shows plausibility warnings defined by the DIR, so entries can be checked while a cycle is still open.
The DIR itself works with MedITEX solutions: the yearbook credits NEXUS / MEDITEX GmbH with keeping the registry's technology and data collection systems up to date (pp. 229-230). With MedITEX Registry, clinics submit their documented data to national registry organizations without duplicate entry, and registry operators can run questionnaires, access control per clinic, statistics and reports. MedITEX solutions report treatment data to the D.I.R. (Germany), DHA (Dubai), FIVNAT (Switzerland), HFEA (United Kingdom), OKFÖ (Hungary) and RetePMA (Italy).
Read the annual reports
- DIR Annual 2025
- DIR Annual 2024
- DIR Annual 2023
- All annual reports and the registry's own website: www.deutsches-ivf-register.de
Learn more about MedITEX and registry reporting
Want to know how MedITEX IVF and MedITEX Registry support registry reporting? Find out more about MedITEX Registry and MedITEX IVF, or get in touch with our sales team: sales@nexus-meditex.de
Source: DIR Annual 2025, J Reproduktionsmed Endokrinol 2026; 23 (6), www.ivf.software/dir-annual-2025. Page numbers refer to the journal pages.





